{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:31:38Z","timestamp":1785904298825,"version":"3.56.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hydroxyurea is one of the earliest drugs that showed promise in the management of haemoglobinopathies that include \u03b2-thalassaemia and sickle cell disease. Despite this, many aspects of hydroxyurea are either unknown or understudied; specifically, its usefulness in \u03b2-thalassaemia major and haemoglobin E \u03b2-thalassaemia is unclear. However, during COVID-19 pandemic, it has become a valuable adjunct to transfusion therapy in patients with \u03b2-haemoglobinopathies. In this review, we aim to explore the available in vitro and in vivo mechanistic data and the clinical utility of hydroxyurea in \u03b2-haemoglobinopathies with a special emphasis on its usefulness during the COVID-19 pandemic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>Hydroxyurea is an S-phase-specific drug that reversibly inhibits ribonucleoside diphosphate reductase enzyme which catalyses an essential step in the DNA biosynthesis. In human erythroid cells, it induces the expression of \u03b3-globin, a fetal globin gene that is suppressed after birth. Through several molecular pathways described in this review, hydroxyurea exerts many favourable effects on the haemoglobin content, red blood cell indices, ineffective erythropoiesis, and blood rheology in patients with \u03b2-haemoglobinopathies. Currently, it is recommended for sickle cell disease and non-transfusion dependent \u03b2-thalassaemia. A number of clinical trials are ongoing to evaluate its usefulness in transfusion dependent \u03b2-thalassaemia. During the COVID-19 pandemic, it was widely used as an adjunct to transfusion therapy due to limitations in the availability of blood and logistical disturbances. Thus, it has become clear that hydroxyurea could play a remarkable role in reducing transfusion requirements of patients with haemoglobinopathies, especially when donor blood is a limited resource.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Hydroxyurea is a well-tolerated oral drug which has been in use for many decades. Through its actions of reversible inhibition of ribonucleoside diphosphate reductase enzyme and fetal haemoglobin induction, it exerts many favourable effects on patients with \u03b2-haemoglobinopathies. It is currently approved for the treatment of sickle cell disease and non-transfusion dependent \u03b2-thalassaemia. Also, there are various observations to suggest that hydroxyurea is an important adjunct in the treatment of transfusion dependent \u03b2-thalassaemia which should be confirmed by randomised clinical trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01757-w","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T18:03:10Z","timestamp":1614621790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["A comprehensive review of hydroxyurea for \u03b2-haemoglobinopathies: the role revisited during COVID-19 pandemic"],"prefix":"10.1186","volume":"16","author":[{"given":"Nirmani","family":"Yasara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Premawardhena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0760-0418","authenticated-orcid":false,"given":"Sachith","family":"Mettananda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"1757_CR1","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827.Hydroxyurea","volume":"14","author":"PT Mcgann","year":"2018","unstructured":"Mcgann PT, Ware RE, Children C. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2018;14:1749\u201358. https:\/\/doi.org\/10.1517\/14740338.2015.1088827.Hydroxyurea.","journal-title":"Expert Opin Drug Saf"},{"key":"1757_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2020.08.008","author":"MA Ali","year":"2020","unstructured":"Ali MA, Ahmad A, Chaudry H, Aiman W, Aamir S, Anwar MY, Khan A. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol. 2020. https:\/\/doi.org\/10.1016\/j.exphem.2020.08.008.","journal-title":"Exp Hematol"},{"key":"1757_CR3","doi-asserted-by":"publisher","first-page":"41958","DOI":"10.1136\/bmjopen-2020-041958","volume":"10","author":"N Yasara","year":"2020","unstructured":"Yasara N, Wickramarathne N, Mettananda C, Manamperi A, Premawardhena A, Mettananda S. Efficacy and safety of oral hydroxyurea in transfusion-dependent \u03b2-thalassaemia: a protocol for randomised double-blind controlled clinical trial. BMJ Open. 2020;10:41958. https:\/\/doi.org\/10.1136\/bmjopen-2020-041958.","journal-title":"BMJ Open"},{"key":"1757_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/nyas.12988","volume":"1368","author":"S Mettananda","year":"2016","unstructured":"Mettananda S, Gibbons RJ, Higgs DR. Understanding \u03b1-globin gene regulation and implications for the treatment of \u03b2-thalassemia. Ann N Y Acad Sci. 2016;1368:16\u201324. https:\/\/doi.org\/10.1111\/nyas.12988.","journal-title":"Ann N Y Acad Sci"},{"key":"1757_CR5","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nat Rev Dis Prim. 2018;4:18010. https:\/\/doi.org\/10.1038\/nrdp.2018.10.","journal-title":"Nat Rev Dis Prim"},{"key":"1757_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.hoc.2017.11.003","volume":"32","author":"S Mettananda","year":"2018","unstructured":"Mettananda S, Higgs DR. Molecular Basis and Genetic Modifiers of Thalassemia. Hematol Oncol Clin North Am. 2018;32:177\u201391. https:\/\/doi.org\/10.1016\/j.hoc.2017.11.003.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1757_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4038\/sljch.v47i2.8484","volume":"47","author":"S Mettananda","year":"2018","unstructured":"Mettananda S. Management of thalassaemia. Sri Lanka J Child Heal. 2018;47:159\u201365. https:\/\/doi.org\/10.4038\/sljch.v47i2.8484.","journal-title":"Sri Lanka J Child Heal"},{"key":"1757_CR8","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMra1510865","volume":"376","author":"FB Piel","year":"2017","unstructured":"Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376:1561\u201373. https:\/\/doi.org\/10.1056\/NEJMra1510865.","journal-title":"N Engl J Med"},{"key":"1757_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41467-017-00479-7","volume":"8","author":"S Mettananda","year":"2017","unstructured":"Mettananda S, Fisher CA, Hay D, Badat M, Quek L, Clark K, Hublitz P, Downes D, Kerry J, Gosden M, Telenius J, Sloane-Stanley JA, Faustino P, Coelho A, Doondeea J, Usukhbayar B, Sopp P, Sharpe JA, Hughes JR, Vyas P, Gibbons RJ, Higgs DR. Editing an \u03b1-globin enhancer in primary human hematopoietic stem cells as a treatment for \u03b2-Thalassemia. Nat Commun. 2017;8:424. https:\/\/doi.org\/10.1038\/s41467-017-00479-7.","journal-title":"Nat Commun"},{"key":"1757_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nature15521","volume":"527","author":"MC Canver","year":"2015","unstructured":"Canver MC, Smith EC, Sher F, Pinello L, Sanjana NE, Shalem O, Chen DD, Schupp PG, Vinjamur DS, Garcia SP, Luc S, Kurita R, Nakamura Y, Fujiwara Y, Maeda T, Yuan GC, Zhang F, Orkin SH, Bauer DE. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature. 2015;527:192\u20137. https:\/\/doi.org\/10.1038\/nature15521.","journal-title":"Nature"},{"key":"1757_CR11","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.3324\/haematol.2016.155655","volume":"102","author":"S Mettananda","year":"2017","unstructured":"Mettananda S, Fisher CA, Sloane-Stanley JA, Taylor S, Oppermann U, Gibbons RJ, Higgs DR. Selective silencing of \u03b1-globin by the histone demethylase inhibitor IOX1: A potentially new pathway for treatment of \u03b2-thalassemia. Haematologica. 2017;102:e80\u20134. https:\/\/doi.org\/10.3324\/haematol.2016.155655.","journal-title":"Haematologica"},{"key":"1757_CR12","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1182\/blood-2019-01-895094","volume":"133","author":"S Xu","year":"2019","unstructured":"Xu S, Luk K, Yao Q, Shen AH, Zeng J, Wu Y, Luo HY, Brendel C, Pinello L, Chui DHK, Wolfe SA, Bauer DE. Editing aberrant splice sites efficiently restores b-globin expression in b-thalassemia. Blood. 2019;133:2255\u201362. https:\/\/doi.org\/10.1182\/blood-2019-01-895094.","journal-title":"Blood"},{"key":"1757_CR13","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1182\/blood-2015-03-633594","volume":"125","author":"S Mettananda","year":"2015","unstructured":"Mettananda S, Gibbons RJ, Higgs DR. \u03b1-Globin as a molecular target in the treatment of \u03b2-thalassemia. Blood. 2015;125:3694\u2013701. https:\/\/doi.org\/10.1182\/blood-2015-03-633594.","journal-title":"Blood"},{"key":"1757_CR14","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1182\/blood-2012-06-292078","volume":"120","author":"DE Bauer","year":"2012","unstructured":"Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin\u202f: prospects for new therapies for the \u2424 -globin disorders. Blood. 2012;120:2945\u201353. https:\/\/doi.org\/10.1182\/blood-2012-06-292078.","journal-title":"Blood"},{"key":"1757_CR15","doi-asserted-by":"publisher","first-page":"11649","DOI":"10.1038\/s41598-019-48204-2","volume":"9","author":"S Mettananda","year":"2019","unstructured":"Mettananda S, Yasara N, Fisher CA, Taylor S, Gibbons R, Higgs D. Synergistic silencing of \u03b1-globin and induction of \u03b3-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for \u03b2-thalassaemia. Sci Rep. 2019;9:11649. https:\/\/doi.org\/10.1038\/s41598-019-48204-2.","journal-title":"Sci Rep"},{"key":"1757_CR16","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.molonc.2016.07.008","volume":"10","author":"M Crona","year":"2016","unstructured":"Crona M, Cod\u00f3 P, Jonna VR, Hofer A, Fernandes AP, Tholander F. A ribonucleotide reductase inhibitor with deoxyribonucleoside-reversible cytotoxicity. Mol Oncol. 2016;10:1375\u201386. https:\/\/doi.org\/10.1016\/j.molonc.2016.07.008.","journal-title":"Mol Oncol"},{"key":"1757_CR17","doi-asserted-by":"publisher","unstructured":"E. Anderes, S. Nand, Commonly used drugs in hematologic disorders, 1st ed., Elsevier B.V., 2014. https:\/\/doi.org\/10.1016\/B978-0-7020-4087-0.00076-0.","DOI":"10.1016\/B978-0-7020-4087-0.00076-0"},{"key":"1757_CR18","doi-asserted-by":"publisher","unstructured":"V. Simeonovski, H. Breshkovska, S. Duma, I. Dohcheva-Karajovanov, K. Damevska, S. Nikolovska, Hydroxyurea Associated Cutaneous Lesions: A Case Report the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), J. Med. Sci. 6 (2018) 1458\u20131461. https:\/\/doi.org\/10.3889\/oamjms.2018.320.","DOI":"10.3889\/oamjms.2018.320"},{"key":"1757_CR19","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2012-10-408021","volume":"121","author":"KM Musallam","year":"2013","unstructured":"Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with \u03b2-thalassemia. Blood. 2013;121:2199\u2013212. https:\/\/doi.org\/10.1182\/blood-2012-10-408021.","journal-title":"Blood"},{"key":"1757_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1040-8428(98)00032-8","volume":"29","author":"P Navarra","year":"1999","unstructured":"Navarra P, Preziosi P. Hydroxyurea: New insights on an old drug. Crit Rev Oncol Hematol. 1999;29:249\u201355. https:\/\/doi.org\/10.1016\/S1040-8428(98)00032-8.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1757_CR21","doi-asserted-by":"publisher","unstructured":"R.K. Agrawal, R.K. Patel, V. Shah, L. Nainiwal, B. Trivedi, R. Kumar, A.\u2022 Rakesh, K. Patel, \u2022 Varsha, \u2022 Lalit, \u2022 N., B. Trivedi, Hydroxyurea in sickle cell disease: Drug review, Indian J. Hematol. Blood Transfus. 30 (2014) 91\u201396. https:\/\/doi.org\/10.1007\/s12288-013-0261-4.","DOI":"10.1007\/s12288-013-0261-4"},{"key":"1757_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2011-03-325258","volume":"118","author":"I Akinsheye","year":"2011","unstructured":"Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, Chui DHK, Steinberg MH. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118:19\u201327. https:\/\/doi.org\/10.1182\/blood-2011-03-325258.","journal-title":"Blood"},{"key":"1757_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3233\/CH-170280","volume":"67","author":"N Lemonne","year":"2017","unstructured":"Lemonne N, M\u00f6ckesch B, Charlot K, Garnier Y, Waltz X, Lamarre Y, Antoine-Jonville S, Etienne-Julan M, Hardy-Dessources M-D, Romana M, Connes P. Effects of hydroxyurea on blood rheology in sickle cell anemia: A two-years follow-up study. Clin Hemorheol Microcirc. 2017;67:141\u20138. https:\/\/doi.org\/10.3233\/CH-170280.","journal-title":"Clin Hemorheol Microcirc"},{"key":"1757_CR24","doi-asserted-by":"publisher","first-page":"252","DOI":"10.5539\/gjhs.v8n3p252","volume":"8","author":"B Keikhaei","year":"2015","unstructured":"Keikhaei B, Yousefi H, Bahadoram M. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia. Glob J Health Sci. 2015;8:252\u20136. https:\/\/doi.org\/10.5539\/gjhs.v8n3p252.","journal-title":"Glob J Health Sci"},{"key":"1757_CR25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3109\/03630269.2010.513638","volume":"34","author":"SK Ballas","year":"2010","unstructured":"Ballas SK, McCarthy WF, Guo N, Brugnara C, Kling G, Bauserman RL, Waclawiw MA. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin. 2010;34:424\u20139. https:\/\/doi.org\/10.3109\/03630269.2010.513638.","journal-title":"Hemoglobin"},{"key":"1757_CR26","doi-asserted-by":"publisher","unstructured":"B. Keikhaei, H. Yousefi, M. Bahadoram, Clinical and haematological effects of hydroxyurea in \u03b2-Thalassemia intermedia patients, J. Clin. Diagnostic Res. 9 (2015) OM01\u2013OM03. https:\/\/doi.org\/10.7860\/JCDR\/2015\/14807.6660.","DOI":"10.7860\/JCDR\/2015\/14807.6660"},{"key":"1757_CR27","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/blood.v128.22.4838.4838","volume":"128","author":"PK Chowdhury","year":"2016","unstructured":"Chowdhury PK, Jena R, Chowdhury D. Red Cell Indices As Predictors of Response to Hydroxyurea Therapy in Hbe\/Beta Thalassaemia Patients. Blood. 2016;128:4838\u20134838. https:\/\/doi.org\/10.1182\/blood.v128.22.4838.4838.","journal-title":"Blood"},{"key":"1757_CR28","doi-asserted-by":"publisher","unstructured":"M. Reza Bordbar, ; Samir Silavizadeh, S. Haghpanah, R. Kamfiroozi, M. Bardestani, ; Mehran Karimi, Hydroxyurea Treatment in Transfusion-Dependent \u03b2-Thalassemia Patients, Iran Red Crescent Med J. 16 (2014) 18028. https:\/\/doi.org\/10.5812\/ircmj.18028.","DOI":"10.5812\/ircmj.18028"},{"key":"1757_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jcph.1297","volume":"59","author":"M Zohaib","year":"2019","unstructured":"Zohaib M, Ansari SH, Shamsi TS, Zubarev RA, Zarina S. Pharmacoproteomics Profiling of Plasma From \u03b2-Thalassemia Patients in Response to Hydroxyurea Treatment. J Clin Pharmacol. 2019;59:98\u2013106. https:\/\/doi.org\/10.1002\/jcph.1297.","journal-title":"J Clin Pharmacol"},{"key":"1757_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0009-8981(03)00005-6","volume":"329","author":"Y Beguin","year":"2003","unstructured":"Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta. 2003;329:9\u201322. https:\/\/doi.org\/10.1016\/S0009-8981(03)00005-6.","journal-title":"Clin Chim Acta"},{"key":"1757_CR31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.beem.2015.09.003","volume":"29","author":"K Harms","year":"2015","unstructured":"Harms K, Kaiser T. Beyond soluble transferrin receptor: Old challenges and new horizons. Best Pract Res Clin Endocrinol Metab. 2015;29:799\u2013810. https:\/\/doi.org\/10.1016\/j.beem.2015.09.003.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1757_CR32","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3389\/fphys.2019.01329","volume":"10","author":"E Nader","year":"2019","unstructured":"Nader E, Skinner S, Romana M, Fort R, Lemonne N, Guillot N, Gauthier A, Antoine-Jonville S, Renoux C, Hardy-Dessources M-D, Stauffer E, Joly P, Bertrand Y, Connes P. Blood Rheology: Key Parameters, Impact on Blood Flow, Role in Sickle Cell Disease and Effects of Exercise. Front Physiol. 2019;10:1329. https:\/\/doi.org\/10.3389\/fphys.2019.01329.","journal-title":"Front Physiol"},{"key":"1757_CR33","doi-asserted-by":"publisher","first-page":"20150065","DOI":"10.1098\/rsfs.2015.0065","volume":"6","author":"X Li","year":"2016","unstructured":"Li X, Du E, Lei H, Tang YH, Dao M, Suresh S, Karniadakis GE. Patient-specific blood rheology in sickle-cell anaemia. Interface Focus. 2016;6:20150065. https:\/\/doi.org\/10.1098\/rsfs.2015.0065.","journal-title":"Interface Focus"},{"key":"1757_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.niox.2018.10.003","volume":"81","author":"E Nader","year":"2019","unstructured":"Nader E, Grau M, Fort R, Collins B, Cannas G, Gauthier A, Walpurgis K, Martin C, Bloch W, Nader E, Grau M, Fort R, Collins B, Cannas G. Hydroxyurea therapy modulates sickle cell anemia red blood cell physiology\u202f: Impact on RBC deformability, oxidative stress, nitrite levels and nitric oxide synthase signalling pathway To cite this version\u202f: HAL Id\u202f: hal-01968408 physiology\u202f: Impact on R. Nitric Oxide. 2019;81:28\u201335. https:\/\/doi.org\/10.1016\/j.niox.2018.10.003.","journal-title":"Nitric Oxide"},{"key":"1757_CR35","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.3324\/haematol.2015.130435","volume":"100","author":"N Lemonne","year":"2015","unstructured":"Lemonne N, Charlot K, Waltz X, Ballas SK, Lamarre Y, Lee K, Hierso R, Connes C, Etienne-Julan M, Romana M, Connes P. Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia. Haematologica. 2015;100:e383\u20136. https:\/\/doi.org\/10.3324\/haematol.2015.130435.","journal-title":"Haematologica"},{"key":"1757_CR36","doi-asserted-by":"publisher","unstructured":"D.K. Wood, A. Soriano, L. Mahadevan, J.M. Higgins, S.N. Bhatia, A biophysical indicator of vaso-occlusive risk in sickle cell disease, Sci. Transl. Med. 4 (2012). https:\/\/doi.org\/https:\/\/doi.org\/10.1126\/scitranslmed.3002738.","DOI":"10.1126\/scitranslmed.3002738"},{"key":"1757_CR37","unstructured":"E.S. Lee, M.M. Heller, F. Kamangar, K. Park, W. Liao, J. Koo, Hydroxyurea for the Treatment of Psoriasis including in HIV-infected Individuals: A Review., Psoriasis Forum. 17 (2011) 180\u2013187. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25346593 (accessed March 23, 2020)."},{"key":"1757_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.hoc.2009.11.002","volume":"24","author":"MM Heeney","year":"2010","unstructured":"Heeney MM, Ware RE. Hydroxyurea for Children with Sickle Cell Disease. Hematol Oncol Clin North Am. 2010;24:199\u2013214. https:\/\/doi.org\/10.1016\/j.hoc.2009.11.002.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1757_CR39","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ajh.24255","volume":"91","author":"L Luchtman-Jones","year":"2016","unstructured":"Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, Hassell K, Davis BR, Ware RE. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. Am J Hematol. 2016;91:238\u201342. https:\/\/doi.org\/10.1002\/ajh.24255.","journal-title":"Am J Hematol"},{"key":"1757_CR40","doi-asserted-by":"publisher","unstructured":"A.E. Ahmed, Y.Z. Ali, A.M. Al-Suliman, J.M. Albagshi, M. Al Salamah, M. Elsayid, W.R. Alanazi, R.A. Ahmed, D.K. McClish, H. Al-Jahdali, The prevalence of abnormal leukocyte count, and its predisposing factors, in patients with sickle cell disease in Saudi Arabia, J. Blood Med. 8 (2017) 185\u2013191. https:\/\/doi.org\/10.2147\/JBM.S148463.","DOI":"10.2147\/JBM.S148463"},{"key":"1757_CR41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2141.2012.09061.x","volume":"157","author":"JM Flanagan","year":"2012","unstructured":"Flanagan JM, Steward S, Howard TA, Mortier NA, Kimble AC, Aygun B, Hankins JS, Neale GA, Ware RE. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia. Br J Haematol. 2012;157:240\u20138. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09061.x.","journal-title":"Br J Haematol"},{"key":"1757_CR42","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1046\/j.1365-2141.2002.03958.x","volume":"119","author":"M Wang","year":"2002","unstructured":"Wang M, Tang DC, Liu W, Chin K, Zhu JG, Fibach E, Rodgers GP. Hydroxyurea exerts bi-modal dose-dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways. Br J Haematol. 2002;119:1098\u2013105. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03958.x.","journal-title":"Br J Haematol"},{"key":"1757_CR43","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00277-012-1671-3","volume":"92","author":"M Banan","year":"2013","unstructured":"Banan M. Hydroxyurea treatment in \u03b2-thalassemia patients: To respond or not to respond? Ann Hematol. 2013;92:289\u201399. https:\/\/doi.org\/10.1007\/s00277-012-1671-3.","journal-title":"Ann Hematol"},{"key":"1757_CR44","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1073\/pnas.041599798","volume":"98","author":"T Ikuta","year":"2001","unstructured":"Ikuta T. Mechanism for fetal globin gene expression: Role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci. 2001;98:1847\u201352. https:\/\/doi.org\/10.1073\/pnas.041599798.","journal-title":"Proc Natl Acad Sci"},{"key":"1757_CR45","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1182\/blood-2013-10-534842","volume":"124","author":"J Zhu","year":"2014","unstructured":"Zhu J, Chin K, Aerbajinai W, Kumkhaek C, Li H, Rodgers GP. Hydroxyurea-inducible SAR1 gene acts through the Gi\u03b1\/JNK\/Jun pathway to regulate \u03b3-globin expression. Blood. 2014;124:1146\u201356. https:\/\/doi.org\/10.1182\/blood-2013-10-534842.","journal-title":"Blood"},{"key":"1757_CR46","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1586\/17474086.2015.1078235","volume":"8","author":"GD Pule","year":"2015","unstructured":"Pule GD, Mowla S, Novitzky N, Wiysonge CS, Wonkam A. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Rev Hematol. 2015;8:669\u201379. https:\/\/doi.org\/10.1586\/17474086.2015.1078235.","journal-title":"Expert Rev Hematol"},{"key":"1757_CR47","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1182\/blood-2011-07-368746","volume":"118","author":"AL Walker","year":"2011","unstructured":"Walker AL, Steward S, Howard TA, Mortier N, Smeltzer M, Wang YD, Ware RE. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia. Blood. 2011;118:5664\u201370. https:\/\/doi.org\/10.1182\/blood-2011-07-368746.","journal-title":"Blood"},{"key":"1757_CR48","doi-asserted-by":"publisher","unstructured":"S.Y. Chen, Y. Wang, M.J. Telen, J.T. Chi, The genomic analysis of erythrocyte microRNA expression in sickle cell diseases, PLoS One. 3 (2008). https:\/\/doi.org\/10.1371\/journal.pone.0002360.","DOI":"10.1371\/journal.pone.0002360"},{"key":"1757_CR49","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/03630269.2017.1290651","volume":"41","author":"MT Hojjati","year":"2017","unstructured":"Hojjati MT, Azarkeivan A, Pourfathollah AA, Amirizadeh N. Comparison of MicroRNAs Mediated in Reactivation of the \u03b3-Globin in \u03b2-Thalassemia Patients. Responders and Non-Responders to Hydroxyurea, Hemoglobin. 2017;41:110\u20135. https:\/\/doi.org\/10.1080\/03630269.2017.1290651.","journal-title":"Responders and Non-Responders to Hydroxyurea, Hemoglobin"},{"key":"1757_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2019.00509","volume":"10","author":"K Mnika","year":"2019","unstructured":"Mnika K, Mazandu GK, Jonas M, Pule GD, Chimusa ER, Hanchard NA, Wonkam A. Hydroxyurea-induced miRNA expression in sickle cell disease patients in Africa. Front Genet. 2019;10:1\u20136. https:\/\/doi.org\/10.3389\/fgene.2019.00509.","journal-title":"Front Genet"},{"key":"1757_CR51","doi-asserted-by":"publisher","unstructured":"N. Saki, S. Abroun, M. Soleimani, M. Kavianpour, M. Shahjahani, J. Mohammadi-Asl, S. Hajizamani, MicroRNA expression in \u03b2-Thalassemia and sickle cell disease: A role in the induction of fetal hemoglobin, Cell J. 17 (2016) 583\u2013592. https:\/\/doi.org\/10.22074\/cellj.2016.3808.","DOI":"10.22074\/cellj.2016.3808"},{"key":"1757_CR52","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1182\/blood.v128.22.1302.1302","volume":"128","author":"S Ragg","year":"2016","unstructured":"Ragg S, Key M, Rankin F, Hulbert ML. Insights from Comparative Serum Proteomic Profiling of Children with Sickle Cell Disease: The Effect of Hydroxyurea and Genotype on Protein Abundance. Blood. 2016;128:1302\u20131302. https:\/\/doi.org\/10.1182\/blood.v128.22.1302.1302.","journal-title":"Blood"},{"key":"1757_CR53","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1586\/epr.10.88","volume":"7","author":"S Yuditskaya","year":"2010","unstructured":"Yuditskaya S, Suffredini AF, Kato GJ. The proteome of sickle cell disease: Insights from exploratory proteomic profiling. Expert Rev Proteomics. 2010;7:833\u201348. https:\/\/doi.org\/10.1586\/epr.10.88.","journal-title":"Expert Rev Proteomics"},{"key":"1757_CR54","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jprot.2009.11.003","volume":"73","author":"SS Ghatpande","year":"2010","unstructured":"Ghatpande SS, Choudhary PK, Quinn CT, Goodman SR. In Vivo Pharmaco-Proteomic Analysis of Hydroxyurea Induced Changes in the Sickle Red Blood Cell Membrane Proteome. J Proteomics. 2010;73:619. https:\/\/doi.org\/10.1016\/j.jprot.2009.11.003.","journal-title":"J Proteomics"},{"key":"1757_CR55","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1182\/blood-2003-08-2760","volume":"104","author":"ML Jison","year":"2004","unstructured":"Jison ML, Munson PJ, Barb JJ, Suffredini AF, Talwar S, Logun C, Raghavachari N, Beigel JH, Shelhamer JH, Danner RL, Gladwin MT. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004;104:270\u201380. https:\/\/doi.org\/10.1182\/blood-2003-08-2760.","journal-title":"Blood"},{"key":"1757_CR56","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1440-1681.2007.04861.x","volume":"35","author":"LS Moreira","year":"2008","unstructured":"Moreira LS, De Andrade TG, Albuquerque DM, Cunha AF, Fattori A, Saad STO, Costa FF. Identification of differentially expressed genes induced by hydroxyurea in reticulocytes from sickle cell anaemia patients. Clin Exp Pharmacol Physiol. 2008;35:651\u20135. https:\/\/doi.org\/10.1111\/j.1440-1681.2007.04861.x.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1757_CR57","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3181\/0807-RM-220","volume":"234","author":"A Hryniewicz-Jankowska","year":"2009","unstructured":"Hryniewicz-Jankowska A, Choudhary PK, Ammann LP, Quinn CT, Goodman SR. Monocyte Protein Signatures of Disease Severity in Sickle Cell Anemia NIH Public Access. Exp Biol Med. 2009;234:210\u201321. https:\/\/doi.org\/10.3181\/0807-RM-220.","journal-title":"Exp Biol Med"},{"key":"1757_CR58","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1182\/blood-2012-02-414037","volume":"121","author":"SC Rogers","year":"2013","unstructured":"Rogers SC, Ross JGC, D\u2019Avignon A, Gibbons LB, Gazit V, Hassan MN, McLaughlin D, Griffin S, Neumayr T, DeBaun M, DeBaun MR, Doctor A. Sickle hemoglobin disturbs normal coupling among erythrocyte O2 content, glycolysis, and antioxidant capacity. Blood. 2013;121:1651\u201362. https:\/\/doi.org\/10.1182\/blood-2012-02-414037.","journal-title":"Blood"},{"key":"1757_CR59","doi-asserted-by":"publisher","unstructured":"G.J. Kato, V. McGowan, R.F. Machado, J.A. Little, J. Taylor VI, C.R. Morris, J.S. Nichols, X. Wang, M. Poljakovic, S.M. Morris, M.T. Gladwin, Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease, Blood. 107 (2006) 2279\u20132285. https:\/\/doi.org\/10.1182\/blood-2005-06-2373.","DOI":"10.1182\/blood-2005-06-2373"},{"key":"1757_CR60","doi-asserted-by":"publisher","unstructured":"J.A. Moreira, M.R. Laurentino, R.P.G. Machado, M.C. Barbosa, R.P. Gon\u00e7alves, A. de M. Mota, L.B. da S. Rocha, A.M.C. Martins, A.B. de Lima Arruda, I.P. de Souza, R.P. Gon\u00e7alves, Pattern of hemolysis parameters and association with fetal hemoglobin in sickle cell anemia patients in steady state, Brazillian J. Hematol. Hemoter. 37 (2015) 167\u2013171. https:\/\/doi.org\/10.1016\/j.bjhh.2015.01.008.","DOI":"10.1016\/j.bjhh.2015.01.008"},{"key":"1757_CR61","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2009-05-221333","volume":"115","author":"E Voskaridou","year":"2010","unstructured":"Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115:2354\u201363. https:\/\/doi.org\/10.1182\/blood-2009-05-221333.","journal-title":"Blood"},{"key":"1757_CR62","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1600-0609.2006.00788.x","volume":"78","author":"S Gambero","year":"2007","unstructured":"Gambero S, Canalli AA, Traina F, Albuquerque DM, Saad STO, Costa FF, Conran N. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. Eur J Haematol. 2007;78:144\u201351. https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00788.x.","journal-title":"Eur J Haematol"},{"key":"1757_CR63","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1046\/j.1365-2141.2000.02040.x","volume":"109","author":"CA Hillery","year":"2000","unstructured":"Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol. 2000;109:322\u20137. https:\/\/doi.org\/10.1046\/j.1365-2141.2000.02040.x.","journal-title":"Br J Haematol"},{"key":"1757_CR64","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ajh.23623","volume":"89","author":"AWY Shih","year":"2014","unstructured":"Shih AWY, Mcfarlane A, Verhovsek M. Haptoglobin testing in hemolysis: Measurement and interpretation. Am J Hematol. 2014;89:443\u20137. https:\/\/doi.org\/10.1002\/ajh.23623.","journal-title":"Am J Hematol"},{"key":"1757_CR65","doi-asserted-by":"publisher","unstructured":"S.M. Ragab, M.A. Safan, E.A. Badr, Study of Serum Haptoglobin Level and its Relation to Erythropoietic Activity in Beta Thalassemia Children, Open J. Syst. Mediterr. J. Hematol. Infect. Dis. Orig. Artic. Erythrop. Act. Beta Thalass. Child. Mediterr J Hematol Infect Dis. 7 (2015) 2015019. https:\/\/doi.org\/10.4084\/MJHID.2015.019.","DOI":"10.4084\/MJHID.2015.019"},{"key":"1757_CR66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0009-8981(01)00586-1","volume":"312","author":"JR Delanghe","year":"2001","unstructured":"Delanghe JR, Langlois MR. Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin Chim Acta. 2001;312:13\u201323. https:\/\/doi.org\/10.1016\/S0009-8981(01)00586-1.","journal-title":"Clin Chim Acta"},{"key":"1757_CR67","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4103\/0971-6866.116128","volume":"19","author":"R Colah","year":"2013","unstructured":"Colah R, Italia K, Jijina F, Merchant R, Swaminathan S, Nadkarni A, Gupta M, Ghosh K. Comparison of in-vitro and in-vivo response to fetal hemoglobin production and \u03b3-mRNA expression by hydroxyurea in Hemoglobinopathies. Indian J Hum Genet. 2013;19:251. https:\/\/doi.org\/10.4103\/0971-6866.116128.","journal-title":"Indian J Hum Genet"},{"key":"1757_CR68","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3324\/haematol.2012.074492","volume":"98","author":"F Pourfarzad","year":"2013","unstructured":"Pourfarzad F, von Lindern M, Azarkeivan A, Hou J, Kia SK, Esteghamat F, van Ijcken W, Philipsen S, Najmabadi H, Grosveld F. Hydroxyurea responsiveness in \u03b2-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica. 2013;98:696\u2013704. https:\/\/doi.org\/10.3324\/haematol.2012.074492.","journal-title":"Haematologica"},{"key":"1757_CR69","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cca.2009.06.019","volume":"407","author":"KY Italia","year":"2009","unstructured":"Italia KY, Jijina FJ, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB. Response to hydroxyurea in \u03b2 thalassemia major and intermedia: Experience in western India. Clin Chim Acta. 2009;407:10\u20135. https:\/\/doi.org\/10.1016\/j.cca.2009.06.019.","journal-title":"Clin Chim Acta"},{"key":"1757_CR70","doi-asserted-by":"publisher","unstructured":"S.J. Nevitt, A.P. Jones, J. Howard, Hydroxyurea (hydroxycarbamide) for sickle cell disease, Cochrane Database Syst. Rev. 2017 (2017). https:\/\/doi.org\/10.1002\/14651858.CD002202.pub2.","DOI":"10.1002\/14651858.CD002202.pub2"},{"key":"1757_CR71","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jpainsymman.2010.03.020","volume":"40","author":"SK Ballas","year":"2010","unstructured":"Ballas SK, Bauserman RL, McCarthy WF, Castro OL, Smith WR, Waclawiw MA. Hydroxyurea and acute painful crises in sickle cell anemia: Effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. J Pain Symptom Manage. 2010;40:870\u201382. https:\/\/doi.org\/10.1016\/j.jpainsymman.2010.03.020.","journal-title":"J Pain Symptom Manage"},{"key":"1757_CR72","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1006\/bcmd.2000.0328","volume":"26","author":"D Loukopoulos","year":"2000","unstructured":"Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I. Reduction of the clinical severity of sickle cell\/\u03b2-thalassemia with hydroxyurea: The experience of a single center in Greece, Blood Cells. Mol Dis. 2000;26:453\u201366. https:\/\/doi.org\/10.1006\/bcmd.2000.0328.","journal-title":"Mol Dis"},{"key":"1757_CR73","doi-asserted-by":"publisher","unstructured":"R. Di Maggio, M.M. Hsieh, X. Zhao, G. Calvaruso, P. Rigano, D. Renda, J.F. Tisdale, A. Maggio, Chronic administration of hydroxyurea (HU) benefits caucasian patients with sickle-beta thalassemia, Int. J. Mol. Sci. 19 (2018). https:\/\/doi.org\/10.3390\/ijms19030681.","DOI":"10.3390\/ijms19030681"},{"key":"1757_CR74","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ajh.20129","volume":"76","author":"N Conran","year":"2004","unstructured":"Conran N, Fattori A, Saad STO, Costa FF. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea. Am J Hematol. 2004;76:343\u20137. https:\/\/doi.org\/10.1002\/ajh.20129.","journal-title":"Am J Hematol"},{"key":"1757_CR75","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.tracli.2008.05.001","volume":"15","author":"J-P Cartron","year":"2008","unstructured":"Cartron J-P, Elion J. Erythroid adhesion molecules in sickle cell disease: Effect of hydroxyurea. Transfus Clin Biol. 2008;15:39\u201350. https:\/\/doi.org\/10.1016\/j.tracli.2008.05.001.","journal-title":"Transfus Clin Biol"},{"key":"1757_CR76","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1182\/blood-2010-04-282095","volume":"116","author":"MT Gladwin","year":"2010","unstructured":"Gladwin MT, Barst RJ, Castro OL, Gordeuk VR, Hillery CA, Kato GJ, Kim-Shapiro DB, Machado R, Morris CR, Steinberg MH, Vichinsky EP. Pulmonary hypertension and NO in sickle cell. Blood. 2010;116:852\u20134. https:\/\/doi.org\/10.1182\/blood-2010-04-282095.","journal-title":"Blood"},{"key":"1757_CR77","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1182\/blood-2015-08-618561","volume":"127","author":"VR Gordeuk","year":"2016","unstructured":"Gordeuk VR, Castro OL, Machado RF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood. 2016;127:820\u20138. https:\/\/doi.org\/10.1182\/blood-2015-08-618561.","journal-title":"Blood"},{"key":"1757_CR78","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/ijms19010182","volume":"19","author":"J Sleiman","year":"2018","unstructured":"Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba A, Cappellini M, Taher A. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. Int J Mol Sci. 2018;19:182. https:\/\/doi.org\/10.3390\/ijms19010182.","journal-title":"Int J Mol Sci"},{"key":"1757_CR79","unstructured":"A. Taher, K. Mussalam, M. Cappellini, eds., Guidelines for the Management of Non Transfusion Dependent Editors of the 2nd Edition, 2nd ed., Thalassaemia international federation, 2018. https:\/\/thalassaemia.org.cy\/download\/guidelines-for-the-management-of-non-transfusion-dependent-thalassaemias-2nd-edition\/."},{"key":"1757_CR80","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3109\/03630269.2013.869229","volume":"38","author":"M Kosaryan","year":"2014","unstructured":"Kosaryan M, Karami H, Zafari M, Yaghobi N. Report on patients with non transfusion-dependent \u03b2-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. Hemoglobin. 2014;38:115\u20138. https:\/\/doi.org\/10.3109\/03630269.2013.869229.","journal-title":"Hemoglobin"},{"key":"1757_CR81","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.hemonc.2017.02.002","volume":"10","author":"AH Algiraigri","year":"2017","unstructured":"Algiraigri AH, Wright NAM, Paolucci EO, Kassam A. Hydroxyurea for nontransfusion-dependent \u03b2-thalassemia: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2017;10:116\u201325. https:\/\/doi.org\/10.1016\/j.hemonc.2017.02.002.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"1757_CR82","unstructured":"A. Taher, E. Vichinsky, K. Musallam, M.D. Cappellini, V. Viprakasit, S.D. Weatherall, Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT), Thalassaemia International Federation, 2019. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24672826 (accessed November 1, 2020)."},{"key":"1757_CR83","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1182\/blood.v124.21.4031.4031","volume":"124","author":"OB Lahoud","year":"2014","unstructured":"Lahoud OB, Willis V, Solomon WB. Phlebotomy and Hydroxyurea for Non-Transfusion Dependent Iron Overload in Beta-Thalassemia Intermedia. Blood. 2014;124:4031\u20134031. https:\/\/doi.org\/10.1182\/blood.v124.21.4031.4031.","journal-title":"Blood"},{"key":"1757_CR84","doi-asserted-by":"publisher","unstructured":"W.C. Foong, J.J. Ho, C.K. Loh, V. Viprakasit, Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias, Cochrane Database Syst. Rev. 2015 (2015). https:\/\/doi.org\/10.1002\/14651858.CD011579.","DOI":"10.1002\/14651858.CD011579"},{"key":"1757_CR85","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1179\/1607845414Y.0000000168","volume":"20","author":"M Karimi","year":"2015","unstructured":"Karimi M, Cohan N, Pishdad P. Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. Hematology. 2015;20:53\u20137. https:\/\/doi.org\/10.1179\/1607845414Y.0000000168.","journal-title":"Hematology"},{"key":"1757_CR86","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00277-002-0501-4","volume":"81","author":"H Cario","year":"2002","unstructured":"Cario H, Wegener M, Debatin KM, Kohne E. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis. Ann Hematol. 2002;81:478\u201382. https:\/\/doi.org\/10.1007\/s00277-002-0501-4.","journal-title":"Ann Hematol"},{"key":"1757_CR87","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00586-010-1357-2","volume":"19","author":"R Haidar","year":"2010","unstructured":"Haidar R, Mhaidli H, Taher AT. Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J. 2010;19:871\u20138. https:\/\/doi.org\/10.1007\/s00586-010-1357-2.","journal-title":"Eur Spine J"},{"key":"1757_CR88","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1182\/blood","volume":"115","author":"AT Taher","year":"2010","unstructured":"Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned M-S, El-Chafic A-H, Fasulo MR, Cappellini MD. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115:1886\u201392. https:\/\/doi.org\/10.1182\/blood.","journal-title":"Blood"},{"key":"1757_CR89","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/08880018.2017.1354948","volume":"34","author":"AH Algiraigri","year":"2017","unstructured":"Algiraigri AH, Wright NAM, Paolucci EO, Kassam A. Hydroxyurea for lifelong transfusion-dependent \u03b2-thalassemia: A meta-analysis. Pediatr Hematol Oncol. 2017;34:435\u201348. https:\/\/doi.org\/10.1080\/08880018.2017.1354948.","journal-title":"Pediatr Hematol Oncol"},{"key":"1757_CR90","doi-asserted-by":"publisher","first-page":"e27643","DOI":"10.1002\/pbc.27643","volume":"66","author":"S Mettananda","year":"2019","unstructured":"Mettananda S, Pathiraja H, Peiris R, Wickramarathne N, Bandara D, de Silva U, Mettananda C, Premawardhena A. Blood transfusion therapy for \u03b2-thalassemia major and hemoglobin E \u03b2-thalassemia: Adequacy, trends, and determinants in Sri Lanka. Pediatr Blood Cancer. 2019;66:e27643. https:\/\/doi.org\/10.1002\/pbc.27643.","journal-title":"Pediatr Blood Cancer"},{"key":"1757_CR91","doi-asserted-by":"publisher","first-page":"e0228733","DOI":"10.1371\/journal.pone.0228733","volume":"15","author":"S Mettananda","year":"2020","unstructured":"Mettananda S, Peiris R, Pathiraja H, Chandradasa M, Bandara D, de Silva U, Mettananda C, Premawardhena A. Psychological morbidity among children with transfusion dependent \u03b2-thalassaemia and their parents in Sri Lanka. PLoS ONE. 2020;15:e0228733. https:\/\/doi.org\/10.1371\/journal.pone.0228733.","journal-title":"PLoS ONE"},{"key":"1757_CR92","doi-asserted-by":"publisher","unstructured":"S.H. Ansari, Z.S. Lassi, S.M. Khowaja, S.O. Adil, T.S. Shamsi, Hydroxyurea (hydroxycarbamide) for transfusion-dependent \u03b2-thalassaemia, Cochrane Database Syst. Rev. 2019 (2019). https:\/\/doi.org\/10.1002\/14651858.CD012064.pub2.","DOI":"10.1002\/14651858.CD012064.pub2"},{"key":"1757_CR93","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2017-03-771857","volume":"130","author":"I Berthaut","year":"2017","unstructured":"Berthaut I, Bachir D, Kotti S, Chalas C, Stankovic K, Eustache F, Ravel C, Habibi A, Brailly-Tabard S, L\u00e9vy-Dutel L, Bleibtreu A, Simon T, Galact\u00e9ros F, Lionnet F, Mandelbaum J. Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment. Blood. 2017;130:2354\u20136. https:\/\/doi.org\/10.1182\/blood-2017-03-771857.","journal-title":"Blood"},{"key":"1757_CR94","doi-asserted-by":"publisher","unstructured":"M.R. DeBaun, Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: A review, Expert Rev. Hematol. 7 (2014). https:\/\/doi.org\/10.1586\/17474086.2014.959922.","DOI":"10.1586\/17474086.2014.959922"},{"key":"1757_CR95","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/aja.2013.73","volume":"15","author":"L Gu","year":"2013","unstructured":"Gu L, Xiong W-T, Wang C, Sun H-X, Li G-F, Liu X. Cistanche deserticola decoction alleviates the testicular toxicity induced by hydroxyurea in male mice. Asian J Androl. 2013;15:838\u201340. https:\/\/doi.org\/10.1038\/aja.2013.73.","journal-title":"Asian J Androl"},{"key":"1757_CR96","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3923\/jpt.2011.409.417","volume":"6","author":"LC Saalu","year":"2011","unstructured":"Saalu LC, Jewo PI, Yama OE, Oguntola JA. Evaluation of the histomorphometric evidences of hydroxyurea-induced testicular cytotoxicity in sprague-dawley rat. J Pharmacol Toxicol. 2011;6:409\u201317. https:\/\/doi.org\/10.3923\/jpt.2011.409.417.","journal-title":"J Pharmacol Toxicol"},{"key":"1757_CR97","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1813598","volume":"380","author":"L Tshilolo","year":"2019","unstructured":"Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE. Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa. N Engl J Med. 2019;380:121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1813598.","journal-title":"N Engl J Med"},{"key":"1757_CR98","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/asheducation-2015.1.436","volume":"2015","author":"RE Ware","year":"2015","unstructured":"Ware RE. Optimizing hydroxyurea therapy for sickle cell anemia. Hematology. 2015;2015:436\u201343. https:\/\/doi.org\/10.1182\/asheducation-2015.1.436.","journal-title":"Hematology"},{"key":"1757_CR99","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/sj.leu.2402168","volume":"15","author":"C Thauvin-Robinet","year":"2001","unstructured":"Thauvin-Robinet C, Maingueneau C, Robert E, Elefant E, Guy H, Caillot D, Casasnovas R, Douvier S, Nivelon-Chevallier A. Exposure to hydroxyurea during pregnancy: a case series. Leukemia. 2001;15:1309\u201311. https:\/\/doi.org\/10.1038\/sj.leu.2402168.","journal-title":"Leukemia"},{"key":"1757_CR100","doi-asserted-by":"publisher","unstructured":"S.O. Gwer, K.O. Onyango, Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol, JBI Database Syst. Rev. Implement. Reports. 16 (2018) 1135\u20131140. https:\/\/doi.org\/10.11124\/JBISRIR-2017-003548.","DOI":"10.11124\/JBISRIR-2017-003548"},{"key":"1757_CR101","doi-asserted-by":"publisher","unstructured":"A. Shander, S.M. Goobie, M.A. Warner, M. Aapro, E. Bisbe, A.A. Perez-Calatayud, J. Callum, M.M. Cushing, W.B. Dyer, J. Erhard, D. Faraoni, S. Farmer, T. Fedorova, S.M. Frank, B. Froessler, H. Gombotz, I. Gross, N.R. Guinn, T. Haas, J. Hamdorf, J.P. Isbister, M. Javidroozi, H. Ji, Y.W. Kim, D.J. Kor, J. Kurz, S. Lasocki, M.F. Leahy, C.K. Lee, J.J. Lee, V. Louw, J. Meier, A. Mezzacasa, M. Munoz, S. Ozawa, M. Pavesi, N. Shander, D.R. Spahn, B.D. Spiess, J. Thomson, K. Trentino, C. Zenger, A. Hofmann, Essential Role of Patient Blood Management in a Pandemic: A Call for Action, Anesth. Analg. (2020) 74\u201385. https:\/\/doi.org\/10.1213\/ANE.0000000000004844.","DOI":"10.1213\/ANE.0000000000004844"},{"key":"1757_CR102","unstructured":"American Red Cross. Coronavirus Outbreak: Help Us Continue to Deliver Our Lifesaving Mission Nationwide Due to This Public Health Emergency, (n.d.). https:\/\/www.redcross.org\/content\/dam\/redcross\/about-us\/disaster-relief\/coronavirus-outbreak-donor-info-sheet-3-18-20.pdf (accessed January 22, 2021)."},{"key":"1757_CR103","doi-asserted-by":"publisher","first-page":"e003042","DOI":"10.1136\/bmjgh-2020-003042","volume":"5","author":"SAKS Ahmed","year":"2020","unstructured":"Ahmed SAKS, Ajisola M, Azeem K, Bakibinga P, Chen Y-F, Choudhury NN, Fayehun O, Griffiths F, Harris B, Kibe P, Lilford RJ, Omigbodun A, Rizvi N, Sartori J, Smith S, Watson SI, Wilson R, Yeboah G, Aujla N, Azam SI, Diggle PJ, Gill P, Iqbal R, Kabaria C, Kisia L, Kyobutungi C, Madan JJ, Mberu B, Mohamed SF, Nazish A, Odubanjo O, Osuh ME, Owoaje E, Oyebode O, Porto de Albuquerque J, Rahman O, Tabani K, Taiwo OJ, Tregonning G, Uthman OA, Yusuf R. Impact of the societal response to COVID-19 on access to healthcare for non-COVID-19 health issues in slum communities of Bangladesh, Kenya, Nigeria and Pakistan: results of pre-COVID and COVID-19 lockdown stakeholder engagements. BMJ Glob Heal. 2020;5:e003042. https:\/\/doi.org\/10.1136\/bmjgh-2020-003042.","journal-title":"BMJ Glob Heal"},{"key":"1757_CR104","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/nejmoa1910182","volume":"382","author":"MD Cappellini","year":"2020","unstructured":"Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew H-K, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew L-P, Bee P-C, Lim S-M, Lu M-Y, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A. A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia. N Engl J Med. 2020;382:1219\u201331. https:\/\/doi.org\/10.1056\/nejmoa1910182.","journal-title":"N Engl J Med"},{"key":"1757_CR105","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1182\/blood.2020005992","volume":"135","author":"MR DeBaun","year":"2020","unstructured":"DeBaun MR. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic. Blood. 2020;135:1997\u20139. https:\/\/doi.org\/10.1182\/blood.2020005992.","journal-title":"Blood"},{"key":"1757_CR106","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1182\/BLOOD.2020006582","volume":"135","author":"RS Nickel","year":"2020","unstructured":"Nickel RS, Margulies S, Frazer B, Luban NLC, Webb J. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic. Blood. 2020;135:2320\u20132. https:\/\/doi.org\/10.1182\/BLOOD.2020006582.","journal-title":"Blood"},{"key":"1757_CR107","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/ejh.13476","volume":"105","author":"D Farmakis","year":"2020","unstructured":"Farmakis D, Giakoumis A, Cannon L, Angastiniotis M, Eleftheriou A. COVID-19 and thalassaemia: a position statement of the Thalassaemia International Federation. Eur J Haematol. 2020;105:378\u201386. https:\/\/doi.org\/10.1111\/ejh.13476.","journal-title":"Eur J Haematol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01757-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01757-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01757-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T18:10:31Z","timestamp":1614622231000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01757-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1757"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01757-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]},"assertion":[{"value":"30 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}